Lung Cancer Trial, Recruiting NCT05010109 Sponsor: M.D. Anderson Cancer Center Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05010109
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with non-small cell lung cancer, small cell lung cancer, or limited stage small cell lung cancer (confirmed by tissue testing)
  • People whose recommended treatment plan includes radiation therapy to the chest area, given at the same time as drug treatment (such as chemotherapy and/or immunotherapy), with or without additional drug treatment given before or after
  • People aged 18 or older
  • People who have a performance status score of 70 or above on the Karnofsky scale — this is a measure of how well a person is able to carry out daily activities (confirm with trial site)
  • People who are willing and able to sign a consent form agreeing to take part
  • People who are willing to complete a 6-minute walking test
  • People who are willing to have a heart marker blood test as part of the study assessments

Who may not be able to join:

  • People who are unable or unwilling to sign a written consent form
  • People who have previously had radiation therapy to the chest in an area that overlaps with the planned treatment area for this trial
  • People who are pregnant or breastfeeding
  • People with kidney failure that requires dialysis
  • People who are unwilling to complete the tests required by the study protocol
  • People for whom any of the required study tests are medically not suitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Zhongxing Liao, MD, M.D. Anderson Cancer Center

Phone: 832-829-5312

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 July 2021
Est. completion
2 February 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Increase in level of hs-TnT >= 5ng/L; Incidence of grade >= 2 cardiovascular events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov